Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

British Journal of Haematology

Volumn 155, Issue 3, 2011, Pages 349-361

  Bae, Jooeun ^a,b   Tai, Yu Tzu ^a,b   Anderson, Kenneth C ^a,b   Munshi, Nikhil C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

CD138 peptide; Cytotoxic T lymphocytes; Multiple myeloma; Peptide vaccine

Indexed keywords

ALANYLLEUCYLTRYPTOPHANYLLEUCYLTRYPTOPHANYLLEUCYLCYSTEINYLALANYLLEUCINE VACCINE; CANCER VACCINE; GAMMA INTERFERON; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE VACCINE; GLYCYLLEUCYLVALYLLEUCYLISOLEUCYLPHENYLALANYLALANYLVALINE VACCINE; HLA A2 ANTIGEN; PEPTIDE VACCINE; SYNDECAN 1; TRYPTOPHANYLLEUCYLTRYPTOPHANYLLEUCYLCYSTEINYLALANYLLEUCYLALANYLLEUCINE VACCINE; UNCLASSIFIED DRUG; VALYLISOLEUCYLALANYLGLYCYLGLYCYLLEUCYLVALYLGLYCYLLEUCINE VACCINE;

AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DRUG CYTOTOXICITY; DRUG SPECIFICITY; DRUG TARGETING; EPITOPE MAPPING; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL DISORDER; PRIORITY JOURNAL;

CANCER VACCINES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; MULTIPLE MYELOMA; PEPTIDE FRAGMENTS; PLASMA CELLS; SYNDECAN-1; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 80053967062     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08850.x     Document Type: Article

References (59)

1. Bae, J., Martinson, J.A. & Klingemann, H.G. (2004) Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cellular Immunology, 227, 38-50.
2. Bae, J., Martinson, J.A. & Klingemann, H.G. (2005) Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clinical Cancer Research, 11, 1629-1638.
3. Bae, J., Carrasco, R., Lee, A.H., Prabhala, R., Tai, Y.T., Anderson, K.C. & Munshi, N.C. (2011) Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia, doi: [Epub ahead of print].
4. Bagratuni, T., Wu, P., Gonzalez de Castro, D., Davenport, E.L., Dickens, N.J., Walker, B.A., Boyd, K., Johnson, D.C., Gregory, W., Morgan, G.J. & Davies, F.E. (2010) XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 116, 250-253.
5. Barber, A., Zhang, T., Megli, C.J., Wu, J., Meehan, K.R. & Sentman, C.L. (2008) Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Experimental Hematology, 36, 1318-1328.
6. Bataille, R., Robillard, N., Avet-Loiseau, H., Harousseau, J.L. & Moreau, P. (2005) CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica, 90, 706-707.
7. Bataille, R., Jego, G., Robillard, N., Barille-Nion, S., Harousseau, J.L., Moreau, P., Amiot, M. & Pellat-Deceunynck, C. (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica, 91, 1234-1240.
8. Bayer-Garner, I.B., Sanderson, R.D., Dhodapkar, M.V., Owens, R.B. & Wilson, C.S. (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Modern Pathology, 14, 1052-1058.
9. Benavides, L.C., Sears, A.K., Gates, J.D., Clifton, G.T., Clive, K.S., Carmichael, M.G., Holmes, J.P., Mittendorf, E.A., Ponniah, S. & Peoples, G.E. (2011) Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Review of Vaccines, 10, 201-210.
10. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M. & Koup, R.A. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. Journal of Immunological Methods, 281, 65-78.
11. Bharti, A.C., Shishodia, S., Reuben, J.M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M. & Aggarwal, B.B. (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 103, 3175-3184.
12. Bolhassani, A., Safaiyan, S. & Rafati, S. (2011) Improvement of different vaccine delivery systems for cancer therapy. Molecular Cancer, 10, 3.
13. Carbone, A., Gaidano, G., Gloghini, A., Larocca, L.M., Capello, D., Canzonieri, V., Antinori, A., Tirelli, U., Falini, B. & Dalla-Favera, R. (1998) Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood, 91, 747-755.
14. Carbone, A., Gloghini, A., Larocca, L.M., Antinori, A., Falini, B., Tirelli, U., Dalla-Favera, R. & Gaidano, G. (1999) Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood, 93, 2319-2326.
15. Carey, D.J., Bendt, K.M. & Stahl, R.C. (1996) The cytoplasmic domain of syndecan-1 is required for cytoskeleton association but not detergent insolubility. Identification of essential cytoplasmic domain residues. The Journal of Biological Chemistry, 271, 15253-15260.
16. Chilosi, M., Adami, F., Lestani, M., Montagna, L., Cimarosto, L., Semenzato, G., Pizzolo, G. & Menestrina, F. (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Modern Pathology, 12, 1101-1106.
17. Disis, M.L., Wallace, D.R., Gooley, T.A., Dang, Y., Slota, M., Lu, H., Coveler, A.L., Childs, J.S., Higgins, D.M., Fintak, P.A., dela Rosa, C., Tietje, K., Link, J., Waisman, J. & Salazar, L.G. (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology, 27, 4685-4692.
18. Dobrzanski, M.J., Reome, J.B., Hylind, J.C., Rewers-Felkins, K.A., Abulsamad, K. & Adams, S.L. (2008) Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. Clinical Immunology, 128, 205-218.
19. Dudek, N.L., Perlmutter, P., Aguilar, M.I., Croft, N.P. & Purcell, A.W. (2010) Epitope discovery and their use in peptide based vaccines. Current Pharmaceutical Design, 16, 3149-3157.
20. Dunphy, C.H., Nies, M.K. & Gabriel, D.A. (2007) Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma. Applied Immunohistochemistry and Molecular Morphology, 15, 248-254.
21. Heerema-McKenney, A., Waldron, J., Hughes, S., Zhan, F., Sawyer, J., Barlogie, B. & Shaughnessy, Jr, J.D. (2010) Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. American Journal of Clinical Pathology, 133, 265-270.
22. Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R.J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.T., Cirstea, D., Raje, N.S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P. & Anderson, K.C. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 15, 4028-4037.
23. Inki, P. & Jalkanen, M. (1996) The role of syndecan-1 in malignancies. Annals of Medicine, 28, 63-67.
24. Kannan, S. & Neelapu, S.S. (2009) Vaccination strategies in follicular lymphoma. Current Hematologic Malignancy Reports, 4, 189-195.
25. Kraj, M., Sokolowska, U., Kopec-Szlezak, J., Poglod, R., Kruk, B., Wozniak, J. & Szpila, T. (2008) Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia & Lymphoma, 49, 298-305.
26. Lee, J.J., Choi, B.H., Kang, H.K., Park, M.S., Park, J.S., Kim, S.K., Pham, T.N., Cho, D., Nam, J.H., Kim, Y.J., Rhee, J.H., Yang, D.H., Kim, Y.K., Kim, H.J. & Chung, I.J. (2007) Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leukemia & Lymphoma, 48, 2022-2031.
27. Liu, W., Litwack, E.D., Stanley, M.J., Langford, J.K., Lander, A.D. & Sanderson, R.D. (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. The Journal of Biological Chemistry, 273, 22825-22832.
28. Mateo, G., Montalban, M.A., Vidriales, M.B., Lahuerta, J.J., Mateos, M.V., Gutierrez, N., Rosinol, L., Montejano, L., Blade, J., Martinez, R., de la Rubia, J., Diaz-Mediavilla, J., Sureda, A., Ribera, J.M., Ojanguren, J.M., de Arriba, F., Palomera, L., Terol, M.J., Orfao, A. & San Miguel, J.F. (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. Journal of Clinical Oncology, 26, 2737-2744.
29. McKenzie, E.A. (2007) Heparanase: a target for drug discovery in cancer and inflammation. British Journal of Pharmacology, 151, 1-14.
30. Moreau, P., Robillard, N., Jego, G., Pellat, C., Le Gouill, S., Thoumi, S., Avet-Loiseau, H., Harousseau, J.L. & Bataille, R. (2006) Lack of CD27 in myeloma delineates different presentation and outcome. British Journal of Haematology, 132, 168-170.
31. Morse, M.A., Secord, A.A., Blackwell, K., Hobeika, A.C., Sinnathamby, G., Osada, T., Hafner, J., Philip, M., Clay, T.M., Lyerly, H.K. & Philip, R. (2011) MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clinical Cancer Research, 17, 3408-3419.
32. Muzio, M., Bertilaccio, M.T., Simonetti, G., Frenquelli, M. & Caligaris-Cappio, F. (2009) The role of toll-like receptors in chronic B-cell malignancies. Leukemia & Lymphoma, 50, 1573-1580.
33. Papandreou, I., Denko, N.C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D.E., Bouley, D.M., Offner, F., Niwa, M. & Koong, A.C. (2011) Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood, 117, 1311-1314.
34. Parvanova, I., Rettig, L., Knuth, A. & Pascolo, S. (2011) The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine, 29, 3832-3836.
35. Patterson, J., Palombella, V.J., Fritz, C. & Normant, E. (2008) IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemotherapy and Pharmacology, 61, 923-932.
36. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J.L., Rapp, M.J., Juge-Morineau, N., Wijdenes, J. & Amiot, M. (1994) Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood, 84, 2597-2603.
37. Perez-Andres, M., Almeida, J., Martin-Ayuso, M., Moro, M.J., Martin-Nunez, G., Galende, J., Hernandez, J., Mateo, G., San Miguel, J.F. & Orfao, A. (2006) Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer, 106, 1296-1305.
38. Rawstron, A.C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R.A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., Kovarova, L., Lioznov, M., Mateo, G., Morilla, R., Mylin, A.K., Omede, P., Pellat-Deceunynck, C., Perez Andres, M., Petrucci, M., Ruggeri, M., Rymkiewicz, G., Schmitz, A., Schreder, M., Seynaeve, C., Spacek, M., de Tute, R.M., Van Valckenborgh, E., Weston-Bell, N., Owen, R.G., San Miguel, J.F., Sonneveld, P. & Johnsen, H.E. (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93, 431-438.
39. Ridley, R.C., Xiao, H., Hata, H., Woodliff, J., Epstein, J. & Sanderson, R.D. (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood, 81, 767-774.
40. Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.J., Harousseau, J.L. & Bataille, R. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, 1070-1071.
41. Roden, M.M., Lee, K.H., Panelli, M.C. & Marincola, F.M. (1999) A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. Journal of Immunological Methods, 226, 29-41.
42. Sanderson, R.D., Lalor, P. & Bernfield, M. (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regulation, 1, 27-35.
43. Sebestyen, A., Mihalik, R., Petak, I. & Kopper, L. (1997) Modulation of apoptosis signaling in etoposide-treated lymphoma cells. Anticancer Research, 17, 2609-2614.
44. el-Shami, K. & Smith, B.D. (2008) Immunotherapy for myeloid leukemias: current status and future directions. Leukemia, 22, 1658-1664.
45. Shukla, N.M., Lewis, T.C., Day, T.P., Mutz, C.A., Ukani, R., Hamilton, C.D., Balakrishna, R. & David, S.A. (2011) Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorganic & Medicinal Chemistry Letters, 21, 3232-3236.
46. Slezak, S.L., Worschech, A., Wang, E., Stroncek, D.F. & Marincola, F.M. (2010) Analysis of vaccine-induced T cells in humans with cancer. Advances in Experimental Medicine and Biology, 684, 178-188.
47. Strothmeyer, A.M., Papaioannou, D., Duhren-von Minden, M., Navarrete, M., Zirlik, K., Heining-Mikesch, K. & Veelken, H. (2010) Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma. Blood, 116, 1734-1736.
48. Sun, W.P., Wang, F.M., Xie, F., Wang, G.Q., Sun, J., Yu, G.H., Qiu, Y.H. & Zhang, X.G. (2007) A novel anti-human syndecan-1 (CD138) monoclonal antibody 4B3: characterization and application. Cellular & Molecular Immunology, 4, 209-214.
49. Supiot, S., Faivre-Chauvet, A., Couturier, O., Heymann, M.F., Robillard, N., Kraeber-Bodere, F., Morandeau, L., Mahe, M.A. & Cherel, M. (2002) Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer, 94, 1202-1209.
50. Svane, I.M., Nikolajsen, K. & Johnsen, H.E. (2007) Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. Scandinavian Journal of Immunology, 66, 465-475.
51. Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. & Anderson, K.C. (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood, 104, 3688-3696.
52. Vooijs, W.C., Post, J., Wijdenes, J., Schuurman, H.J., Bolognesi, A., Polito, L., Stirpe, F., Bast, E.J. & de Gast, G.C. (1996) Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunology, Immunotherapy, 42, 319-328.
53. Wang, S., Hong, S., Wezeman, M., Qian, J., Yang, J. & Yi, Q. (2007) Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Frontiers in Bioscience, 12, 3566-3575.
54. Westers, T.M., van den Ancker, W., Bontkes, H.J., Janssen, J.J., van de Loosdrecht, A.A. & Ossenkoppele, G.J. (2011) Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy, 3, 569-576.
55. Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R.X., Klein, B. & Dore, J.M. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. British Journal of Haematology, 94, 318-323.
56. Wolowiec, D., Dybko, J., Wrobel, T., Urbaniak-Kujda, D., Jazwiec, B., Tomaszewska-Toporska, B., Kapelko-Slowik, K., Potoczek, S. & Kuliczkowski, K. (2006) Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators of Inflammation, 2006, 42394.
57. Yang, Y., MacLeod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z., Venkataraman, G., Sasisekharan, R., Naggi, A., Torri, G., Casu, B., Vlodavsky, I., Suva, L.J., Epstein, J., Yaccoby, S., Shaughnessy, Jr, J.D., Barlogie, B. & Sanderson, R.D. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood, 110, 2041-2048.
58. Yi, Q., Szmania, S., Freeman, J., Qian, J., Rosen, N.A., Viswamitra, S., Cottler-Fox, M., Barlogie, B., Tricot, G. & van Rhee, F. (2010) Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. British Journal of Haematology, 150, 554-564.
59. Zweerink, H.J., Gammon, M.C., Utz, U., Sauma, S.Y., Harrer, T., Hawkins, J.C., Johnson, R.P., Sirotina, A., Hermes, J.D., Walker, B.D. & Biddisont, W.E. (1993) Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. Journal of Immunology, 150, 1763-1771.